Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCAR3 | P49019 | 15/20 | 1.00 |
| ▸ | HCAR2 | Q8TDS4 | 2/20 | 0.60 |
| ▸ | PTGER4 | P35408 | 1/20 | 0.52 |
| ▸ | GCK | P35557 | 2/20 | 0.50 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28782092 | 0.89 | HCAR3 (0.81) | HCAR3HCAR2PTGER4ADRA1AKDM4E | |
| SCHEMBL12686854 | 0.88 | HCAR3 (0.78) | HCAR3HCAR2PTGER4ADRA1AKDM4E | |
| SCHEMBL12953967 | 0.87 | HCAR3 (0.76) | HCAR3ADRA1AKDM4EALDH1A1 | |
| SCHEMBL24218510 | 0.87 | HCAR3 (0.76) | HCAR3HCAR2ADRA1AKDM4EALDH1A1 | |
| SCHEMBL12678699 | 0.87 | HCAR3 (0.76) | HCAR3HCAR2ADRA1AKDM4EALDH1A1 | |
| SCHEMBL17365710 | 0.83 | HCAR3 (0.71) | HCAR3PTGER4ADRA1AKDM4EALDH1A1 | |
| Bromide SCHEMBL16753989 | 0.83 | HCAR3 (0.71) | HCAR3HCAR2ADRA1AKDM4EALDH1A1 | |
| SCHEMBL186474 | 0.83 | HCAR3 (1.00) | HCAR3HCAR2 | |
| SCHEMBL18193683 | 0.81 | HCAR3 (0.74) | HCAR3HCAR2 | |
| SCHEMBL7230169 | 0.81 | HCAR3 (0.73) | HCAR3HCAR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9624198-B2 | Substituted piperidinyltetrahydroquinolines | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2017-04-18 | — | — | US | disclosed |
| US-9624198-B2 | Substituted piperidinyltetrahydroquinolines | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2017-04-18 | — | — | US | disclosed |
| US-9624198-B2 | Substituted piperidinyltetrahydroquinolines | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2017-04-18 | — | — | US | disclosed |
| US-9624199-B2 | Substituted bipiperidinyl derivatives | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2017-04-18 | — | — | US | disclosed |
| US-9624199-B2 | Substituted bipiperidinyl derivatives | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2017-04-18 | — | — | US | disclosed |
| US-9624199-B2 | Substituted bipiperidinyl derivatives | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2017-04-18 | — | — | US | disclosed |
| EP-3083593-A1 | SUBSTITUTED PIPERIDINYL-TETRAHYDROQUINOLINES | Bayer Pharma Aktiengesellschaft (DE) | 2016-10-26 | — | — | EP | disclosed |
| EP-3083610-A1 | SUBSTITUTED BIPIPERIDINYL DERIVATIVES AS ADRENORECEPTOR ALPHA 2C ANTAGONISTS | Bayer Pharma Aktiengesellschaft (DE) | 2016-10-26 | — | — | EP | disclosed |
| US-20160304491-A1 | SUBSTITUTED PIPERIDINYLTETRAHYDROQUINOLINES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2016-10-20 | — | — | US | disclosed |
| US-20160304491-A1 | SUBSTITUTED PIPERIDINYLTETRAHYDROQUINOLINES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2016-10-20 | — | — | US | disclosed |
| US-20160304492-A1 | SUBSTITUTED BIPIPERIDINYL DERIVATIVES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2016-10-20 | — | — | US | disclosed |
| US-20160304491-A1 | SUBSTITUTED PIPERIDINYLTETRAHYDROQUINOLINES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2016-10-20 | — | — | US | disclosed |
| WO-2015091417-A1 | SUBSTITUTED PIPERIDINYL-TETRAHYDROQUINOLINES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2015-06-25 | — | — | WO | disclosed |
| WO-2015091417-A1 | SUBSTITUTED PIPERIDINYL-TETRAHYDROQUINOLINES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2015-06-25 | — | — | WO | disclosed |
| WO-2015091420-A1 | SUBSTITUTED BIPIPERIDINYL DERIVATIVES AS ADRENORECEPTOR ALPHA 2C ANTAGONISTS | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2015-06-25 | — | — | WO | disclosed |
| WO-2015091420-A1 | SUBSTITUTED BIPIPERIDINYL DERIVATIVES AS ADRENORECEPTOR ALPHA 2C ANTAGONISTS | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2015-06-25 | — | — | WO | disclosed |
| US-8273773-B2 | Heterocyclic antiviral compounds | ROCHE PALO ALTO LLC (US) | 2012-09-25 | — | — | US | disclosed |
| EP-2307372-B1 | HETEROCYCLIC ANTIVIRAL COMPOUNDS | HOFFMANN LA ROCHE (CH) | 2012-04-25 | — | — | EP | disclosed |
| CN-102099335-A | Heterocyclic antiviral compounds | HOFFMANN LA ROCHE | 2011-06-15 | — | — | CN | disclosed |
| US-20100021423-A1 | Heterocyclic antiviral compounds | ROCHE PALO ALTO LLC | 2010-01-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160304492-A1 | SUBSTITUTED BIPIPERIDINYL DERIVATIVES | TNNC1, TNNI3, FABP3 | HCAR3 1348/4885HCAR2 2689/4885PTGER4 1430/4885 |
| US-20100021423-A1 | Heterocyclic antiviral compounds | POLR2A, RRM2B, RRP1B | HCAR3 2486/4885HCAR2 3185/4885PTGER4 3614/4885 |
| US-20160304491-A1 | SUBSTITUTED PIPERIDINYLTETRAHYDROQUINOLINES | TNNI3, TNNC1, PRPH | HCAR3 2858/4885HCAR2 3641/4885PTGER4 750/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.